Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22060529 | 0.84 | EP300 (0.34) | EP300ADASMN1; SMN2KDRPDE2A | |
| SCHEMBL24529739 | 0.84 | EP300 (0.34) | EP300ADASMN1; SMN2KDRPDE2A | |
| SCHEMBL8269531 | 0.75 | SMN1; SMN2 (0.40) | EP300ADASMN1; SMN2PDE2ACYP3A4 | |
| SCHEMBL23809316 | 0.75 | KDM4E (0.31) | KDM4EALDH1A1HSD17B10TSHR | |
| SCHEMBL18671993 | 0.74 | FGFR1 (0.39) | ADA | |
| SCHEMBL19590215 | 0.74 | FGFR1 (0.39) | ADA | |
| SCHEMBL20334783 | 0.74 | FGFR1 (0.39) | ADA | |
| SCHEMBL22348797 | 0.73 | GPR84 (0.37) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23187794 | 0.73 | GPR84 (0.37) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23106274 | 0.73 | KDM4E (0.31) | KDM4EHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365211-B2 | Stereoselective synthesis and process for the manufacturing of 2′-deoxynucleosides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200361977-A1 | STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-19 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | EP300 1865/4885ADA 26/4885SMN1; SMN2 2411/4885 |
| US-11365211-B2 | Stereoselective synthesis and process for the manufacturing of 2′-deoxynucleosides | DCTD, DUT, TET1 | EP300 3984/4885ADA 37/4885SMN1; SMN2 2387/4885 |
| US-20200361977-A1 | STEREOSELECTIVE SYNTHESIS AND PROCESS FOR THE MANUFACTURING OF 2'-DEOXYNUCLEOSIDES | DCTD, DUT, TET1 | EP300 4006/4885ADA 37/4885SMN1; SMN2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.